English

Contineum Therapeutics, Inc.

EDGAR

CTNM Quarterly report (10-Q) · filed 2026-07-30

Annual consolidated revenue for 2024: about USD 0, using the latest reported figures. The previous period, 2023, was about USD 50M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-10.2 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -32845000 USD Source
Operating Cash Flow: -22643000 USD Source

Free cash flow

-10.4 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -32845000 USD Source
Operating Cash Flow: -22643000 USD Source
Capital Expenditure: 514000 USD Source
Capital Expenditure: 348000 USD Source

Cash and cash equivalents: 14.7 million USD 2026-06-30 Source
Exact value

14711000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 2.38 million shares 2024-03-31 Source
Exact value

2384426 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-57.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -12800000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -60000000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -44800000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -14456000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -15200000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-53 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -42270000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -30073000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -55312000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -42270000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -16266000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -27767000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -16266000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

458 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 189000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 91000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 231000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 189000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 312000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 318000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 312000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-53.5 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -42270000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -30073000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -55312000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -42270000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -16266000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -27767000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -16266000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 189000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 91000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 231000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 189000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 312000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 318000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 312000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-07-30.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 2 of 11 periods available· newest 2024-12-31
Operating income: 2 of 11 periods available· newest 2024-12-31
Net income: 2 of 11 periods available· newest 2024-12-31
Operating cash flow: 2 of 11 periods available· newest 2024-12-31
Capital expenditure: 2 of 11 periods available· newest 2024-12-31
Total assets: 2 of 11 periods available· newest 2024-12-31
Total liabilities: 2 of 11 periods available· newest 2024-12-31
Current assets: 2 of 11 periods available· newest 2024-12-31
Current liabilities: 2 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 2 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 1 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 50 million

2023-01-01 – 2023-12-31
Current period

USD 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 50000000 = -50000000 USD

50000000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Year-over-year change in Revenue: -50000000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1356053 Filing: 000143774925006458 Input fundies:Revenue: 50000000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1356766 Filing: 000143774925006458
The citation records this snapshot. The page link may show a newer release later.
Net income
-286%

Prior period

USD 22.72 million

2023-01-01 – 2023-12-31
Current period

−USD 42.26 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-42258000 − 22720000 = -64978000 USD

22720000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-42258000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Year-over-year change in Net income: -64978000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -42258000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1278622 Filing: 000162828026015165 Input fundies:NetIncome: 22720000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#2213836 Filing: 000143774925006458
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-269.8%

Prior period

USD 19.35 million

2023-01-01 – 2023-12-31
Current period

−USD 32.85 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-32845000 − 19349000 = -52194000 USD

19349000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-32845000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Year-over-year change in Operating cash flow: -52194000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -32845000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1297402 Filing: 000162828026015165 Input fundies:OperatingCashFlow: 19349000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1569892 Filing: 000143774925006458
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+24.2%

Prior period

USD 414,000

2023-01-01 – 2023-12-31
Current period

USD 514,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

514000 − 414000 = 100000 USD

414000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
514000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Year-over-year change in Capital expenditure: 100000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 514000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1299251 Filing: 000162828026015165 Input fundies:CapitalExpenditure: 414000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1572720 Filing: 000143774925006458
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 0
Operating costs Derived USD 50.89 million
Operating income −USD 50.89 million
Tax, interest and other Derived −USD 8.64 million
Net income −USD 42.26 million

Cash

Operating cash flow −USD 32.85 million
Capital expenditure USD 514,000
Free cash flow Derived −USD 33.36 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Net income was higher than operating income, so the split is not drawn.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	50000000	33923000 Derived	16077000	-6643000 Derived	22720000	18935000 Derived	Source 2023-01-01 – 2023-12-31: 50000000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: 16077000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: 22720000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 19349000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 414000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	50894000 Derived	-50894000	-8636000 Derived	-42258000	-33359000 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -50894000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -42258000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -32845000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 514000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Revenue	50000000	Revenue: 50000000 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 50000000 Open source
20242024-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 50000000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 32.2% 2023

Net margin 45.4% 2023

Free cash flow margin 37.9% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	32.2%	Operating Income: 16077000 Open source Revenue: 50000000 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -50894000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	45.4%	Net Income: 22720000 Open source Revenue: 50000000 Open source
20242024-12-31	Net margin	Not reported	Net Income: -42258000 Open source Revenue: 0 Open source
20232023-12-31	Free cash flow margin	37.9%	Revenue: 50000000 Open source Operating Cash Flow: 19349000 Open source Capital Expenditure: 414000 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -32845000 Open source Capital Expenditure: 514000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -32.8M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Operating cash flow	19349000	Operating Cash Flow: 19349000 Open source
20242024-12-31	Operating cash flow	-32845000	Operating Cash Flow: -32845000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -33.4M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Free cash flow	18935000	Operating Cash Flow: 19349000 Open source Capital Expenditure: 414000 Open source
20242024-12-31	Free cash flow	-33359000	Operating Cash Flow: -32845000 Open source Capital Expenditure: 514000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

6.9% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Liabilities / assets	4.4%	Total Liabilities: 5702000 Open source Total Assets: 130386000 Open source
20242024-12-31	Liabilities / assets	6.9%	Total Liabilities: 14781000 Open source Total Assets: 212847000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

20.69× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Current assets / current liabilities	23.29×	Current Assets: 127706000 Open source Current Liabilities: 5484000 Open source
20242024-12-31	Current assets / current liabilities	20.69×	Current Assets: 206388000 Open source Current Liabilities: 9974000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	USD 22.72 million Exact value Exact value: 22720000 USD 2023-01-01 – 2023-12-31: 22720000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Contineum Therapeutics, Inc. · 2023-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Net Income: 22720000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: 22720000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#2213836 Filing: 000143774925006458 The citation records this snapshot. The page link may show a newer release later.	USD 19.35 million Exact value Exact value: 19349000 USD 2023-01-01 – 2023-12-31: 19349000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Contineum Therapeutics, Inc. · 2023-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Operating Cash Flow: 19349000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 19349000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1569892 Filing: 000143774925006458 The citation records this snapshot. The page link may show a newer release later.	USD 414,000 Exact value Exact value: 414000 USD 2023-01-01 – 2023-12-31: 414000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Contineum Therapeutics, Inc. · 2023-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Capital Expenditure: 414000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 414000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1572720 Filing: 000143774925006458 The citation records this snapshot. The page link may show a newer release later.	USD 18.94 million Calculation and evidence 19349000 − 414000 USD Exact free cash flow: 18935000 USD 2023-01-01 – 2023-12-31: 19349000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 414000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Contineum Therapeutics, Inc. · 2023-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Free cash flow: 18935000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 19349000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1569892 Filing: 000143774925006458 Input fundies:CapitalExpenditure: 414000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000143774925006458/cont20241231_10k.htm#1572720 Filing: 000143774925006458 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 42.26 million Exact value Exact value: -42258000 USD 2024-01-01 – 2024-12-31: -42258000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Net Income: -42258000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -42258000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1278622 Filing: 000162828026015165 The citation records this snapshot. The page link may show a newer release later.	−USD 32.85 million Exact value Exact value: -32845000 USD 2024-01-01 – 2024-12-31: -32845000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Operating Cash Flow: -32845000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -32845000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1297402 Filing: 000162828026015165 The citation records this snapshot. The page link may show a newer release later.	USD 514,000 Exact value Exact value: 514000 USD 2024-01-01 – 2024-12-31: 514000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Capital Expenditure: 514000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 514000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1299251 Filing: 000162828026015165 The citation records this snapshot. The page link may show a newer release later.	−USD 33.36 million Calculation and evidence -32845000 − 514000 USD Exact free cash flow: -33359000 USD 2024-01-01 – 2024-12-31: -32845000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 514000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Contineum Therapeutics, Inc. · 2024-12-31 Contineum Therapeutics, Inc. (edgar:1855175) Free cash flow: -33359000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:45:34Z Snapshot: 4abf2fbea26e2077cb644c92b3335b8185f18f7f30826e1662754a511743aaa1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1855175?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32845000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1297402 Filing: 000162828026015165 Input fundies:CapitalExpenditure: 514000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1855175/000162828026015165/ctnm-20251231.htm#1299251 Filing: 000162828026015165 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

14 filings · 774 latest values · 774 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001855175, 1855175, CTNM, edgar:1855175

Also known as Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation